Pinealon

Pinealon is a synthetic tripeptide (Glu-Asp-Arg) claimed to regulate pineal gland function and circadian rhythms. Developed in Russia. Very limited published data.

PubMed results: 15 · Human studies: 8 · Animal studies: 13

Ranges reflect protocols studied in published research and animal-model extrapolation. Presented for research purposes only, not a recommendation or instruction for human use.

Doses studied in published research. Information presented for research purposes only, not a recommendation for human use.

• Oral / sublingual (research and Russian bioregulator literature) — standard range No well-standardized published human dosing, Not established in controlled Western clinical literature. Sparse quantified protocols in accessible peer-reviewed sources. Russian bioregulator/gerontology literature and commercial research materials sometimes cite multi-milligram daily courses over days to weeks, but these are poorly documented relative to modern trial standards. Prefer treating dosing as unestablished for research framing rather than a fixed human range.

Not established in humans (theoretical confidence)

Pinealon (Glu-Asp-Arg) is a short synthetic bioregulatory tripeptide; no peer-reviewed human pharmacokinetic study defining plasma half-life was identified. Short peptides of this class are generally expected to clear rapidly, but that is theoretical without measured PK.

• Pineal gland function research (Limited): Pinealon is a synthetic tripeptide (Glu-Asp-Arg) developed in Russian bioregulator research programs and claimed to influence pineal gland function; published independent data remain very limited
• Circadian rhythm pathway hypotheses (Theoretical): As a pineal-targeted short peptide in the Khavinson-type series, research interest includes circadian rhythm regulation and sleep–wake endocrine patterning, primarily from limited historical or regional sources
• Neuroendocrine aging research context (Limited): Russian peptide bioregulator literature has explored pinealon in age-related neuroendocrine models; modern controlled trials and independent replication are scarce

• No robust documented human adverse profile — Mild, Not established. Published human safety datasets for pinealon are sparse; formal adverse-event rates are not established in modern controlled literature
• Injection site reactions (research contexts) — Mild, Anecdotal. When studied as a peptide preparation, mild local injection-site reactions are theoretically possible though systematically reported rates are limited

• Insufficient modern clinical safety characterization (Theoretical / Preclinical): Very limited published data and limited independent human evidence mean firm clinical contraindications beyond general investigational peptide research cautions are not established
• Uncontrolled sleep or endocrine disorders under evaluation (Theoretical / Preclinical): Hypotheses around pineal and circadian regulation raise theoretical concern that concurrent experimental use could confound assessment of primary sleep or endocrine endpoints

Lyophilized (powder): Refrigerated (2-8°C), Up to 24 months. Light sensitive: yes, store dark

Reconstituted (solution): Refrigerated (2-8°C), 4-6 weeks. Solvent: Bacteriostatic water